Literature DB >> 18460882

Atopic dermatitis in 2008.

Lawrence S Chan1.   

Abstract

Atopic dermatitis (also termed atopic eczema and infantile eczema), a chronic, itchy, inflammatory skin disease that sets on at infancy or early childhood, is observed with increasing prevalence around the world, particularly in developed nations. Although sufficient evidences are not yet available to define it as a classical autoimmune disease, autoantigens have been identified. Investigations of atopic dermatitis in human patients and animal models suggest that this disease is initiated, maintained and perpetuated by the actions of cytokines, chemokines, T cells, antigen-presenting cells and other inflammatory cells; there is also evidence of skin barrier defect and angiogenesis. Recent identification of mutations of the epidermal barrier protein filaggrin (encoded by FLG), present in about 9% of people of European origin, with 70% of individuals homozygous or compound heterozygous for FLG null alleles developing atopic dermatitis, provides a strong link between a defect of the epidermal barrier that allows easy penetration of pathogen/allergen through the skin and a systemic hyperactive immune response to the penetrated pathogen/allergen. The newly introduced concept of 'intrinsic' and 'extrinsic' atopic dermatitis has fueled the debate among academic dermatologists as to how 'atopic' atopic dermatitis should be defined. Some recent advancements on the management options for atopic dermatitis are also discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460882     DOI: 10.1159/000131450

Source DB:  PubMed          Journal:  Curr Dir Autoimmun        ISSN: 1422-2132


  9 in total

1.  Interleukin-4 Downregulation of Involucrin Expression in Human Epidermal Keratinocytes Involves Stat6 Sequestration of the Coactivator CREB-Binding Protein.

Authors:  Lei Bao; Jaime B Alexander; Huayi Zhang; Kui Shen; Lawrence S Chan
Journal:  J Interferon Cytokine Res       Date:  2016-02-26       Impact factor: 2.607

Review 2.  Animal models of skin disease for drug discovery.

Authors:  Pinar Avci; Magesh Sadasivam; Asheesh Gupta; Wanessa Cma De Melo; Ying-Ying Huang; Rui Yin; Rakkiyappan Chandran; Raj Kumar; Ayodeji Otufowora; Theodore Nyame; Michael R Hamblin
Journal:  Expert Opin Drug Discov       Date:  2013-01-08       Impact factor: 6.098

3.  Cyclosporin treatment of atopic dermatitis: is it really associated with infectious diseases?

Authors:  Shin Woo Kim; Young Woon Park; In Ho Kwon; Kyu Han Kim
Journal:  Ann Dermatol       Date:  2010-05-17       Impact factor: 1.444

4.  Evaluation of Nisin F in the Treatment of Subcutaneous Skin Infections, as Monitored by Using a Bioluminescent Strain of Staphylococcus aureus.

Authors:  M de Kwaadsteniet; C A van Reenen; L M T Dicks
Journal:  Probiotics Antimicrob Proteins       Date:  2009-08-13       Impact factor: 4.609

5.  Oral administration of Lactobacillus plantarum lysates attenuates the development of atopic dermatitis lesions in mouse models.

Authors:  Hangeun Kim; Hye Rim Kim; Na-Ra Kim; Bong Jun Jeong; Jong Suk Lee; Soojin Jang; Dae Kyun Chung
Journal:  J Microbiol       Date:  2014-12-04       Impact factor: 3.422

6.  An important role of blood and lymphatic vessels in inflammation and allergy.

Authors:  Silvana Zgraggen; Alexandra M Ochsenbein; Michael Detmar
Journal:  J Allergy (Cairo)       Date:  2013-01-31

Review 7.  The cutaneous vascular system in chronic skin inflammation.

Authors:  Reto Huggenberger; Michael Detmar
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

8.  Prevalence of atopic dermatitis in infants during the first six months of life: authors' observations.

Authors:  Barbara Kamer; Renata Pasowska; Elżbieta Dółka; Agnieszka Blomberg; Helena Rotsztejn
Journal:  Postepy Dermatol Alergol       Date:  2013-10-30       Impact factor: 1.837

9.  Obstructive sleep apnea and the risk of atopic dermatitis: a population-based case control study.

Authors:  Kai-Jen Tien; Chien-Wen Chou; Shang-Yu Lee; Nai-Cheng Yeh; Chwen-Yi Yang; Feng-Chieh Yen; Jhi-Joung Wang; Shih-Feng Weng
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.